AREV Life Sciences Global Corp.
AREVF · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $4 | $8 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $4 | $8 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -299.9% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 1,519.8% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 1,103.9% |
| EPS Diluted | -0.001 | -0.004 | -0.005 | 0.003 |
| % Growth | 76.3% | 28.3% | -312% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |